A Basolo1, S Heinitz2,3, E J Stinson2, B Begaye2, M Hohenadel2, P Piaggi2, J Krakoff2, S B Votruba2. 1. Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA. alessio.basolo@nih.gov. 2. Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health (NIH), 4212 N. 16th Street, Phoenix, AZ, 85016, USA. 3. Department of Medicine, Division of Endocrinology and Nephrology, University of Leipzig, 1Liebigstr. 18, 04103, Leipzig, Germany.
Abstract
PURPOSE: Glucagon-like peptide 1 (GLP-1) is an incretin hormone that appears to play a major role in the control of food intake. The aim of this investigation was to evaluate and quantify the association of circulating GLP-1 concentration with ad libitum total calorie and macronutrient intake. METHODS: One-hundred and fifteen individuals (72 men) aged 35 ± 10 years were admitted for an inpatient study investigating the determinants of energy intake. Ad libitum food intake was assessed during 3 days using a reproducible vending machine paradigm. Fasting plasma GLP-1 concentrations were measured on the morning of the first day and on the morning of the fourth day after ad libitum feeding. RESULTS: Plasma GLP-1 concentrations increased by 14% after 3 days of ad libitum food intake. Individuals overate on average 139 ± 45% of weight-maintaining energy needs. Fasting plasma GLP-1 on day 1 was negatively associated with carbohydrate intake (r = - 0.2, p = 0.03) and with daily energy intake from low fat-high simple sugar (r = - 0.22, p = 0.016). CONCLUSION: Higher plasma GLP-1 concentrations prior to ad libitum food intake were associated with lower carbohydrate intake and lower simple sugar ingestion, indicating a possible role of the GLP-1 in the reward pathway regulating simple sugar intake. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00342732.
PURPOSE:Glucagon-like peptide 1 (GLP-1) is an incretin hormone that appears to play a major role in the control of food intake. The aim of this investigation was to evaluate and quantify the association of circulating GLP-1 concentration with ad libitum total calorie and macronutrient intake. METHODS: One-hundred and fifteen individuals (72 men) aged 35 ± 10 years were admitted for an inpatient study investigating the determinants of energy intake. Ad libitum food intake was assessed during 3 days using a reproducible vending machine paradigm. Fasting plasma GLP-1 concentrations were measured on the morning of the first day and on the morning of the fourth day after ad libitum feeding. RESULTS: Plasma GLP-1 concentrations increased by 14% after 3 days of ad libitum food intake. Individuals overate on average 139 ± 45% of weight-maintaining energy needs. Fasting plasma GLP-1 on day 1 was negatively associated with carbohydrate intake (r = - 0.2, p = 0.03) and with daily energy intake from low fat-high simple sugar (r = - 0.22, p = 0.016). CONCLUSION: Higher plasma GLP-1 concentrations prior to ad libitum food intake were associated with lower carbohydrate intake and lower simple sugar ingestion, indicating a possible role of the GLP-1 in the reward pathway regulating simple sugar intake. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00342732.
Entities:
Keywords:
Ad libitum food intake; Carbohydrates intake; Glucagon-like peptide 1
Authors: Caroline R Abbott; Mariana Monteiro; Caroline J Small; Arshia Sajedi; Kirsty L Smith; James R C Parkinson; Mohammad A Ghatei; Stephen R Bloom Journal: Brain Res Date: 2005-04-07 Impact factor: 3.252
Authors: E Näslund; B Barkeling; N King; M Gutniak; J E Blundell; J J Holst; S Rössner; P M Hellström Journal: Int J Obes Relat Metab Disord Date: 1999-03
Authors: C Verdich; A Flint; J P Gutzwiller; E Näslund; C Beglinger; P M Hellström; S J Long; L M Morgan; J J Holst; A Astrup Journal: J Clin Endocrinol Metab Date: 2001-09 Impact factor: 5.958
Authors: Alessio Basolo; Maximilian Hohenadel; Qi Yan Ang; Paolo Piaggi; Sascha Heinitz; Mary Walter; Peter Walter; Shannon Parrington; Donovan D Trinidad; Reiner Jumpertz von Schwartzenberg; Peter J Turnbaugh; Jonathan Krakoff Journal: Nat Med Date: 2020-03-23 Impact factor: 53.440